MEI Pharma, Inc. - Common Stock (MEIP)
5.9200
+1.4200 (31.56%)
NASDAQ · Last Trade: Jul 18th, 5:44 PM EDT
MEI Pharma, Inc. (NASDAQ:MEIP) stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.
Via Benzinga · July 18, 2025
MEI Pharma intends to use the funds to acquire the native cryptocurrency of the Litecoin blockchain, commonly referred to as “LTC”, which will serve as the company’s primary treasury reserve asset.
Via Stocktwits · July 18, 2025
MEI Pharma (NASDAQ:MEIP) has launched a $100 million Litecoin (CRYPTO: LTC) treasury program, backed by Titan Partners Group and
Via Benzinga · July 18, 2025
Via Benzinga · July 17, 2025
Via Benzinga · June 30, 2025

Darwin Financial's Joshua Robinson talks to Benzinga about the firm's latest commodities deal, and more M&A news from this past week.
Via Benzinga · November 22, 2024

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has the latest M&A updates.
Via Benzinga · November 17, 2024

Via Benzinga · October 25, 2024

Via Benzinga · July 22, 2024

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via InvestorPlace · July 1, 2024

Via Benzinga · May 16, 2024

MEIP stock results show that MEI Pharma beat analyst estimates for earnings per share the third quarter of 2024.
Via InvestorPlace · May 9, 2024

Via Benzinga · November 16, 2023

Via Benzinga · November 16, 2023

Companies Reporting Before The Bell • Ferguson (NYSE:FERG) is estimated to report quarterly earnings at $2.46 per share on revenue of $7.60 billion.
Via Benzinga · September 26, 2023

Infinity Pharmaceuticals Inc (NASDAQ: INFI) announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the
Via Benzinga · July 10, 2023

MEI Pharma Inc (NASDAQ: MEIP) announced an update to the Phase 1 study of voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, in patients with relapsed and refractory (R/R) acute myeloid leukemia (AML)
Via Benzinga · May 23, 2023

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Via Benzinga · April 24, 2023

MEI Pharma (NASDAQ: MEIP) shares are trading lower by roughly 2.54% to $4.68 Monday morning, though rebounding off the session low of $4.30, after the company announced and effected a 1-for-20 reverse stock split.
Via Benzinga · April 17, 2023